Paeds Cases · growth-development-and-behaviour
Intellectual developmental disorder OSCE — diagnosis counselling and care planning
OSCE on explaining IDD criteria, opening supports, outlining aetiological evaluation and safety-netting.
On this page & tools
Target exams
Station objectives
- Elicit adaptive and developmental history that can support an IDD formulation. [5]
- Explain that IDD needs intellectual and adaptive criteria, not IQ alone. [5]
- Start supports without waiting for every genetic result. [1] [16]
- Outline first-line aetiological testing including microarray. [2] [3]
- Use clear, non-stigmatising language and safety-net regression or acute change. [1]
Candidate brief
You are the paediatric doctor in clinic. Station A is 10 minutes with a parent and child history focus. Station B is 8 minutes of explanation and shared planning after psychology testing confirms intellectual developmental disorder of mild severity by adaptive support need. [5]
Station A — History and formulation
Setup: Six-year-old referred for “slow learning.” Parent says homework is impossible. Child still needs help with buttons and wiping. Hearing screen at school was incomplete. No regression. English is the second language for the parent. [1] [19]
- Offer a professional interpreter before detailed history if language discordance is present. [19]
- Map conceptual, social and practical adaptive examples. [5]
- Ask pregnancy, neonatal, milestone, seizure, family history and school trajectory. [1]
- Check hearing/vision status and prior developmental services. [1]
- Avoid diagnosing from school report alone. [5]
- Signal that supports can start while assessment continues. [16]
Station B — Counselling after diagnosis
Setup: Formal cognitive and adaptive testing supports mild intellectual developmental disorder. Parent asks, “Does this mean he cannot learn anything?” and “Can we wait for the gene test before therapy?” [5] [1]
- Explain IDD in plain language: thinking skills and everyday skills both affected, present from development, severity by support need. [5]
- State hope and specificity: children learn; they need the right teaching and supports. [5]
- Plan education adjustments, therapy referrals and care coordination. [16]
- Outline CMA as first-tier genetics; mention possible later exome/genome sequencing per specialist pathway. [2] [3]
- Refuse the “wait for genetics before help” trap. [1]
- Safety-net: return sooner for skill loss, new seizures, major behaviour change or safety concerns. [1]
- Teach-back the plan and name owners/dates. [16]
Examiner marking cues
- Uses adaptive domains, not IQ-only language. [5]
- Parallel intervention + aetiology. [1] [2]
- Interpreter when needed. [19]
- No false certainty about a single cause before testing. [3]
References
- [1]Moeschler JB Comprehensive evaluation of the child with intellectual disability or global developmental delays. Pediatrics, 2014.PMID 25157020
- [2]Miller DT Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. American journal of human genetics, 2010.PMID 20466091
- [3]Manickam K Exome and genome sequencing for pediatric patients with congenital anomalies or intellectual disability: an evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG). Genetics in medicine, 2021.PMID 34211152
- [5]Tassé MJ The Relation Between Intellectual Functioning and Adaptive Behavior in the Diagnosis of Intellectual Disability. Intellectual and developmental disabilities, 2016.PMID 27893317
- [16]Council on Children with Disabilities and Medical Home Implementation Project Advisory Committee Patient- and family-centered care coordination: a framework for integrating care for children and youth across multiple systems. Pediatrics, 2014.PMID 24777209
- [19]Boylen S Impact of professional interpreters on outcomes for hospitalized children from migrant and refugee families with limited English proficiency: a systematic review. JBI evidence synthesis, 2020.PMID 32813387